Table 5.
Univariate and multivariate logistic regression for an LVEF improvement of at least 10% between prescription and three-month follow-up with the delta of HRV5 and CL measured within the first 45 days of WCD wear time; WCD = wearable cardioverter–defibrillator; LVEF = left ventricular ejection fraction; SD = standard deviation; CL = cycle length; ICM = ischemic cardiomyopathy; HRV5 = heart rate variability approximate. In 10 patients no exact LVEF at three months was available and thus no response could be classified. p-values given are for logistic regression models, see text.
| Parameters | LVEF Improvement < 10% (n = 143) | LVEF Improvement ≥ 10% (n = 118) | p-Value (uni) | Odds Ratio in Multivariate Analysis (95%-CI) | p-Value (Multi) |
|---|---|---|---|---|---|
| Female Sex (n, %) | 39 (27.3%) | 47 (39.8%) | 0.032 | 1.02 (0.51–2.05) | 0.95 |
| Age (mean ± SD) | 60.9 ± 14.3 | 52.6 ± 15.5 | <0.001 | 0.98 (0.96–1.01) per year |
0.130 |
| ICM (n, %) | 69 (48.3%) | 22 (18.6%) | <0.001 | 0.39 (0.18–0.84) | 0.018 |
| Baseline LVEF (%; mean ± SD) | 27.0 ± 8.4 | 22.5 ± 7.1 | <0.001 | 0.92 (0.88–0.96) per percentage point |
<0.001 |
| ∆HRV5 (ms; mean ± SD) | 12.9 ± 39.9 | 38.8 ± 42.2 | <0.001 | 2.13 (1.05–4.32) for ∆HRV5 > 23 ms |
0.035 |
| ∆CL (ms; mean ± SD) | 28.1 ± 119.0 | 54.6 ± 154.4 | <0.001 | 1.98 (0.89–4.44) for ∆CL > 112 ms |
0.093 |
| ∆steps (n; mean ± SD) | 1470 ± 3322 | 3287 ± 4057 | 0.002 | 1.94 (0.99–3.86) for ∆steps > 1163 |
0.054 |